Product Description: Lucicebtide (Compound ST101) is a selective antagonist for CCAAT/enhancer binding protein β (C/EBPβ). Lucicebtide binds to the leucine zipper domain of C/EBPβ, prevents its dimerization, and ubiquitin-dependently degrades C/EBPβ. Lucicebtide arrests cell cycle at G0/G1 phase. Lucicebtide exhibits cytotoxicity in cancer cells. Lucicebtide exhibits good pharmacokinetic characters and inhibits tumor growth in mouse model[1].
Applications: Cancer-programmed cell death
Formula: C208H345N69O55S
References: [1]Darvishi E, et al., Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β. Mol Cancer Ther. 2022 Nov 3;21(11):1632-1644.
CAS Number: 2407100-74-5
Molecular Weight: 4724.46
Compound Purity: 98.28
Research Area: Cancer
Solubility: DMSO : 0.99 mg/mL (ultrasonic;adjust pH to 5 with 1 M HCL)
Target: Others
English
Deutsch
